Omics phenotyping in heart failure: the next frontier
Antoni Bayes-Genis, Peter P Liu, David E Lanfear, Rudolf A de Boer, Arantxa González, Thomas Thum, Michele Emdin, James L Januzzi
This state-of-the-art review aims to provide an up-to-date look at breakthrough omic technologies that are helping to unravel heart failure (HF) disease mechanisms and heterogeneity. Genomics, transcriptomics, proteomics, and metabolomics in HF are reviewed in depth. In addition, there is a thorough, expert discussion regarding the value of omics in identifying novel disease pathways, advancing understanding of disease mechanisms, differentiating HF phenotypes, yielding biomarkers for diagnosis or prognosis, or identifying new therapeutic targets in HF.
The combination of multiple omics technologies may create a more comprehensive picture of the factors and physiology involved in HF than achieved by either one alone and provides a rich resource for predictive phenotype modelling. However, the successful translation of omics tools as solutions to clinical HF requires that the observations are robust and reproducible and can be validated across multiple independent populations to ensure confidence in clinical decision-making.
CITA DEL ARTÍCULO Eur Heart J. 2020 Sep 21;41(36):3477-3484. https://doi.org/10.1093/eurheartj/ehaa270